Platform for isolation and characterization of SARS-CoV-2 variants enables rapid characterization of Omicron in Australia
-
Published:2022-05-30
Issue:6
Volume:7
Page:896-908
-
ISSN:2058-5276
-
Container-title:Nature Microbiology
-
language:en
-
Short-container-title:Nat Microbiol
Author:
Aggarwal Anupriya, Stella Alberto Ospina, Walker Gregory, Akerman Anouschka, Esneau Camille, Milogiannakis Vanessa, Burnett Deborah L., McAllery Samantha, Silva Mariana RuizORCID, Lu Yonghui, Foster Charles S. P., Brilot Fabienne, Pillay Aleha, Van Hal SabastiaanORCID, Mathivanan Vennila, Fichter Christina, Kindinger Andrea, Hoppe Alexandra Carey, Munier Mee LingORCID, Amatayakul-Chantler SupavadeeORCID, Roth Nathan, Coppola Germano, Symonds Geoff P., Schofield Peter, Jackson Jennifer, Lenthall Helen, Henry Jake Y., Mazigi Ohan, Jäck Hans-Martin, Davenport Miles P., Darley David R.ORCID, Matthews Gail V., Khoury David S., Cromer Deborah, Goodnow Christopher C., Christ Daniel, Robosa RoselleORCID, Starck Damien J., Bartlett Nathan W., Rawlinson William D., Kelleher Anthony D., Turville Stuart G.ORCID
Abstract
AbstractGenetically distinct variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have emerged since the start of the COVID-19 pandemic. Over this period, we developed a rapid platform (R-20) for viral isolation and characterization using primary remnant diagnostic swabs. This, combined with quarantine testing and genomics surveillance, enabled the rapid isolation and characterization of all major SARS-CoV-2 variants circulating in Australia in 2021. Our platform facilitated viral variant isolation, rapid resolution of variant fitness using nasopharyngeal swabs and ranking of evasion of neutralizing antibodies. In late 2021, variant of concern Omicron (B1.1.529) emerged. Using our platform, we detected and characterized SARS-CoV-2 VOC Omicron. We show that Omicron effectively evades neutralization antibodies and has a different entry route that is TMPRSS2-independent. Our low-cost platform is available to all and can detect all variants of SARS-CoV-2 studied so far, with the main limitation being that our platform still requires appropriate biocontainment.
Publisher
Springer Science and Business Media LLC
Subject
Cell Biology,Microbiology (medical),Genetics,Applied Microbiology and Biotechnology,Immunology,Microbiology
Cited by
30 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|